Key result
Intravenous NKH477 increases cardiac index ~32% in severe heart failure.
Why the study?
The efficacy and safety of NKH477, a water soluble forskolin derivative, in patients with severe heart failure required evaluation.
Does intravenous NKH477 improve hemodynamics and what is the optimal dose in patients with severe heart failure?
Does intravenous NKH477 improve hemodynamics and what is the optimal dose in patients with severe heart failure?
Intravenous NKH477 improves hemodynamics in severe heart failure, with an optimal clinical dose of 0.5 μg/kg/min balancing efficacy and safety.
Answers are grounded in this paper and cite their sources.
May support acute hemodynamic management in severe HF; hypothesis-generating and requires RCTs before practice change.
To evaluate the efficacy and safety of NKH 477, a water soluble forskolin derivative, a multicenter group study was conducted in 62 patients with severe heart failure.Patients were intravenously administered NKH477 at a rate of 0.25μg/kg/min (low) initially and the dose was increased hourly to 0.5μg/kg/min (intermediate) and finally to 0.75μg/kg/min (high).NKH477 improved the hemodynamics in the patients with severe heart failure, since this agent directly activates adenylate cyclase. The cardiac index (CI) increased significantly and pulmonary capillary wedge pressure (PCWP) and systemic vascular resistance (SVR) were significantly decreased.In the principal physicians' assessment of the global improvement, the percentage of patients judged as “improved” or higher was 19.0% in the low-dose group, 49.1% in the intermediate-dose group and 70.6% in the high-dose group.Adverse events occurred in 6.5% in the low-dose group, 19.7% in the intermediatedose group and 37.0% in the high-dose group, increasing with dose. The most common symptoms were palpitation, flush and headache. It is important to also note an increment of arrhythmias.In the evaluation of usefulness based on the grobal improvement and overall safety, the percentage of patients in which the treatment was assessed as “useful” or higher was 22.4% in the low-dose group, 52.6% in the intermediate-dose group which showed significant increase and 70.6% in the high-dose group.In conclusion, the clinical optimal dose of NKH 477 is thought to be 0.5μg/kg/min.
No takes yet. Share an insight, caveat, or question.
Takano et al. (1997) studied Acute heart failure (n=62). NKH477 vs. Baseline was evaluated on Cardiac index at 0.5 µg/kg/min (L/min/m2) (p=<0.01). Intravenous NKH477 dose-dependently improved hemodynamics in patients with severe heart failure, increasing cardiac index from 2.47 to 3.25 L/min/m2 at the optimal dose of /kg/min.
Synapse has enriched 10 related papers. Consider them for comparative context: